USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Progenika Biopharma, S.a.

USPTO PatentsView assignee record - 10 granted patents across 8 technology areas, active 2015–2025. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: C12Q (MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS ; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICR).

Compiled byPlainPatent Editorial, US Patent Intelligence Editorial Team

Explore the portfolio See the ranking

Total patents granted

CPC technology areas

17.4

Avg claims per patent

-33%

5-year filing velocity

The verdict

Progenika holds 10 US patents across 8 technology areas, rank #27,112 of 50,000 tracked assignees.

#27,112
of 50,000 US assignees by volume: Top 72%
by Innovation Score (28.7/100): 17.4
avg claims per patent: -33%
filing velocity, last 5 yrs

Portfolio overview

Progenika Biopharma, S.a. has been granted 10 US utility patents between 2015 and 2025, placing Progenika Biopharma, S.a. at rank #27,112 across all assignees tracked by PlainPatent. This portfolio spans 8 distinct Cooperative Patent Classification (CPC) subclasses, averaging 17.4 claims per patent with primary concentration in C12Q (MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS ; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICR). As a Foreign Corporation, Progenika Biopharma, S.a. is one of the more focused assignees in the PatentsView dataset. By volume, Progenika sits between Pranalytica, Inc. (10 patents, rank #27,108) and Prosper Creative Co., Ltd. (10 patents, rank #27,116) - the closest US assignees by grant volume. The composite Innovation Score of 28.7/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.

Filing cadence tells the strategic story. Between 2020 and 2025 the company received 4 grants, compared with 6 in the 2015–2019 window, a -33% shift in five-year velocity. A cooling filing rate may reflect portfolio consolidation, shifting priorities, or reduced R&D throughput. The Foreign Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.

Claim depth and technology breadth together indicate competitive posture. Progenika Biopharma, S.a.'s 17.4 average claims per patent sits within the typical range for solid legal coverage without excessive prosecution cost, while concentration in 8 subclasses points to a focused technical program. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Progenika Biopharma, S.a. against peers pursuing similar technology classes.

Pranalytica

10
Predictive Safety…

10
Premier

10
Preventive Medica…

10
Progressive FOAM

10
Propagenix

10
Propeller

10
Prosper Creative

10
Progenika Biophar… ◀

10

What this shows Progenika holds 10 patents at rank #27,112, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Progenika

By rank, the assignees closest to #27,112 in granted patent volume.

Leaders in C12Q (Measuring OR Testing Processes Involving Enzymes)

Other assignees with the most granted patents in Progenika's primary technology class.

Progenika's Innovation Score vs. every tracked assignee

Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)

29 Top 72% higher than 28% of 50,000 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

Progenika Biopharma, S.a. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	2	20.0%
2016	1	10.0%
2017	1	10.0%
2019	2	20.0%
2020	2	20.0%
2025	2	20.0%

Which technologies does Progenika Biopharma, S.a. patent most?

C12Q - MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS ; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES 7

G01N - INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES 4

G16B - BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY 2

C12N - MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA 1

C07K - PEPTIDES 1

A61K - PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES 1

Y02A - TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE 1

G16H - HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA 1

Top 8 of 8 technology areas

Patent Moat Analysis

Portfolio Volume Light

Tech Breadth Focused

Claim Depth Standard

Velocity Declining

Where it ranks

Overall rank by patents

#27,112

Across all tracked assignees

Innovation Score

28.7 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

Frequently Asked Questions

How many patents does Progenika Biopharma, S.a. hold?

Progenika Biopharma, S.a. holds 10 US granted patents filed between 2015 and 2025, spanning 8 technology areas.

What is Progenika Biopharma, S.a.'s Innovation Score?

Progenika Biopharma, S.a. has an Innovation Score of 28.7 out of 100. This composite metric weighs portfolio volume (40%), filing velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Progenika Biopharma, S.a. focus on?

Progenika Biopharma, S.a.'s top technology area is C12Q (MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS ; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES) with 7 patents. The company has filed patents in 8 CPC subclasses total.

Is Progenika Biopharma, S.a.'s patent filing rate increasing or decreasing?

Progenika Biopharma, S.a.'s recent filing velocity is -33% compared to the prior five-year period. Filing activity has slowed relative to earlier years.

What does claim depth mean for Progenika Biopharma, S.a.'s patents?

Progenika Biopharma, S.a.'s patents average 17.4 claims each. This falls within the standard range, providing solid legal coverage.

How is the Progenika Biopharma, S.a. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

How to use this portfolio

Progenika's 10 grants land it in the top 72% by Innovation Score, but volume alone doesn't tell you where the strength sits.

Read that count against the largest US assignees before treating it as dominance - Progenika ranks #27,112 of 50,000. Top 50 holders
Most of this portfolio concentrates in C12Q - see who else leads that technology area. C12Q leaders
Check what the four-part Innovation Score actually rewards before comparing it to another company. How the score works

Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent Editorial

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled byPlainPatent Editorial, US Patent Intelligence Editorial Team

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.